Trials that use: Log-rank test
New to this method? Read the tutorial →
220 results
- NAVIGATE ESUSIndependent statistical analysis of NAVIGATE ESUS, a randomized phase 3 trial comparing rivaroxaban with aspirin in patients with recent embolic stroke of undetermined source, including time-to-event methods, primary and secondary results, safety,…
- NIAGARAIndependent statistical analysis of the phase 3 NIAGARA trial of durvalumab plus gemcitabine/cisplatin in muscle invasive bladder cancer, covering pathologic complete response, event-free survival, secondary endpoints, methodology, and interpretation.
- NO16968Independent statistical analysis of NO16968 (NCT00069121), a randomized phase 3 trial of capecitabine plus oxaliplatin versus 5-FU/LV in colorectal cancer, including disease-free survival, relapse-free survival, overall survival, statistical methodology, and interpretation.
- OCEANSIndependent statistical analysis of the OCEANS phase 3 trial of carboplatin and gemcitabine plus bevacizumab versus placebo in patients with ovary, peritoneal, or fallopian tube carcinoma, including PFS, objective response, overall survival,…
- ODYSSEY OUTCOMESComplete statistical analysis of ODYSSEY OUTCOMES, the randomized phase 3 trial of alirocumab versus placebo after acute coronary syndrome, including time-to-event endpoints, hazard ratios, stratified log-rank testing, multiplicity, safety, and statistical interpretation.
- OlympiAComplete statistical analysis of the OlympiA phase 3 trial of adjuvant olaparib versus placebo in patients with germline BRCA-mutated high-risk HER2-negative primary breast cancer, including trial design, time-to-event endpoints, statistical methods, reported…
- OlympiADIndependent statistical analysis of the OlympiAD phase 3 trial of olaparib monotherapy versus physician's choice chemotherapy in metastatic breast cancer patients with germline BRCA1/2 mutations.
- ORIGINComplete statistical analysis of the ORIGIN phase 3 trial, including its factorial design, cardiovascular and diabetes endpoints, Cox and log-rank methods, odds ratios, confidence intervals, and statistical interpretation.
- PACIFICComplete statistical analysis of the PACIFIC phase 3 trial of MEDI4736 following concurrent chemoradiation in patients with stage III unresectable non-small cell lung cancer, including primary endpoints, time-to-event methods, secondary analyses, safety,…
- PALLASIndependent statistical analysis of PALLAS (NCT02513394), a randomized phase 3 trial of palbociclib plus standard adjuvant endocrine therapy versus endocrine therapy alone in HR+/HER2- invasive early breast cancer.
- PALOMA-2Independent statistical analysis of PALOMA-2 (NCT01740427), a randomized phase 3 trial of palbociclib plus letrozole versus placebo plus letrozole in postmenopausal women with ER+/HER2- advanced breast cancer.
- PALOMA-4Independent statistical analysis of PALOMA-4, a randomized phase 3 trial comparing palbociclib plus letrozole with placebo plus letrozole in Asian postmenopausal women with ER+/HER2- advanced breast cancer.
- PAPILLONIndependent statistical analysis of the phase 3 PAPILLON trial of amivantamab plus chemotherapy versus chemotherapy alone in advanced or metastatic non-small cell lung cancer characterized by EGFR exon 20 insertions.
- PATENT-1Independent statistical analysis of PATENT-1, a randomized phase 3 trial of oral riociguat in patients with pulmonary arterial hypertension, covering its 6-minute walking distance endpoint, ANCOVA, nonparametric and stratified analyses, secondary outcomes,…
- PIONEER AF-PCIComplete statistical analysis of PIONEER AF-PCI, the randomized phase 3 trial evaluating rivaroxaban-based strategies versus vitamin K antagonist therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention.
- POINTComplete statistical analysis of the POINT phase 3 trial of clopidogrel versus placebo in transient ischemic attack, including trial design, 90-day efficacy and hemorrhage endpoints, hazard ratios, confidence intervals, log-rank testing, and…
- POSEIDONIndependent statistical analysis of the phase 3 POSEIDON trial of durvalumab plus tremelimumab with chemotherapy, durvalumab with chemotherapy, or chemotherapy alone in non-small cell lung cancer, including survival, response, methodology, and interpretation.
- PREVAILIndependent statistical analysis of the phase 3 PREVAIL trial of enzalutamide versus placebo in chemotherapy-naive patients with progressive metastatic prostate cancer, including time-to-event endpoints, response analyses, safety, and statistical interpretation.
- PROCLAIMIndependent statistical analysis of the PROCLAIM phase 3 trial, including its randomized design, overall survival analysis, progression-free survival, response, relapse patterns, swallowing outcomes, safety, statistical methods, and interpretation.
- PROFILE 1014Independent statistical analysis of PROFILE 1014, evaluating crizotinib versus pemetrexed plus cisplatin or carboplatin in ALK-positive non-squamous lung cancer, with detailed interpretation of progression-free survival, overall survival, response, patient-reported outcomes, and statistical…
- PROpelIndependent statistical analysis of the PROpel phase 3 trial of olaparib plus abiraterone in men with metastatic castration-resistant prostate cancer, including randomized trial design, radiological progression-free survival, overall survival, secondary time-to-event endpoints,…
- PROSPERIndependent statistical analysis of the phase 3 PROSPER trial of enzalutamide versus placebo in nonmetastatic castration-resistant prostate cancer, including metastasis-free survival, secondary time-to-event endpoints, PSA response, statistical methodology, and interpretation.
- QUAZAR AML-001Independent statistical analysis of QUAZAR AML-001, a randomized phase 3 trial of oral azacitidine plus best supportive care versus placebo plus best supportive care as maintenance therapy in acute myeloid leukemia in…
- RATIONALE-301Independent statistical analysis of RATIONALE-301, a randomized phase 3 trial of tislelizumab versus sorafenib in participants with unresectable hepatocellular carcinoma, including overall survival, response, progression, quality of life, and the trial's non-inferiority…
- RATIONALE-303Independent statistical analysis of RATIONALE-303, a randomized phase 3 trial comparing tislelizumab with docetaxel in second- or third-line non-small cell lung cancer, including overall survival, response, progression-free survival, quality of life, and…
- REACHIndependent statistical analysis of the phase 3 REACH trial of ramucirumab plus best supportive care versus placebo plus best supportive care as second-line treatment for hepatocellular carcinoma after sorafenib.
- REACH-2Independent statistical analysis of REACH-2, a randomized phase 3 trial of ramucirumab plus best supportive care versus placebo plus best supportive care in hepatocellular carcinoma with elevated baseline alpha-fetoprotein.
- REDUCE-ITComplete statistical analysis of REDUCE-IT (NCT01492361), a randomized phase 3 trial of AMR101 versus placebo in high-risk patients with cardiovascular disease and hypertriglyceridemia on statin therapy.
- RELATIVITY-047Independent statistical analysis of RELATIVITY-047, evaluating relatlimab plus nivolumab versus nivolumab alone in participants with advanced melanoma, including trial design, progression-free survival, statistical methodology, interpretation, and limitations.
- RESORCEIndependent statistical analysis of the phase 3 RESORCE trial of regorafenib versus placebo in hepatocellular carcinoma, including overall survival, time to progression, progression-free survival, tumor response, statistical methodology, and interpretation.
- REVEALIndependent statistical analysis of the phase 3 REVEAL trial of anacetrapib versus placebo in atherosclerotic cardiovascular disease, including trial design, time-to-event endpoints, log-rank analysis, rate ratios, confidence intervals, safety, and statistical interpretation.
- RTOG 0617Independent statistical analysis of RTOG 0617, evaluating radiation therapy dose and cetuximab with chemotherapy in newly diagnosed unresectable stage III non-small cell lung cancer, with emphasis on survival, competing risks, safety, and…
- RTOG 0825Independent statistical analysis of RTOG 0825, a randomized phase 3 trial of temozolomide and radiation therapy with or without bevacizumab in patients with newly diagnosed glioblastoma.
- S-TRACIndependent statistical analysis of the S-TRAC phase 3 trial of sunitinib versus placebo in patients at high risk of recurrent renal cell cancer, including disease-free survival, overall survival, trial design, Cox modeling,…
- SEQUOIAIndependent statistical analysis of the phase 3 SEQUOIA trial comparing zanubrutinib with bendamustine plus rituximab in previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma, including its progression-free survival analysis and statistical…
- SERAPHINIndependent statistical analysis of SERAPHIN, the randomized phase 3 trial of macitentan in symptomatic pulmonary arterial hypertension, including time-to-event endpoints, hazard ratios, confidence intervals, log-rank testing, and interpretation.
- SHARPIndependent statistical analysis of SHARP, the randomized phase 3 study of sorafenib versus placebo in patients with advanced hepatocellular carcinoma, including its overall survival and symptomatic progression endpoints, stratified log-rank methodology, interim…
- SKYSCRAPER-02Independent statistical analysis of SKYSCRAPER-02, a randomized phase 3 trial of tiragolumab plus atezolizumab with carboplatin and etoposide versus placebo plus atezolizumab with carboplatin and etoposide in untreated extensive-stage small cell lung…
- SKYSCRAPER-06Independent statistical analysis of SKYSCRAPER-06, evaluating tiragolumab plus atezolizumab and chemotherapy versus pembrolizumab plus chemotherapy in previously untreated advanced non-squamous NSCLC, with detailed interpretation of PFS, OS, response, quality-of-life, and safety analyses.
- SOFTIndependent statistical analysis of the SOFT phase 3 trial of tamoxifen, tamoxifen plus ovarian function suppression, and exemestane plus ovarian function suppression in premenopausal women with hormone-responsive breast cancer.
- SOLAR-1Independent statistical analysis of the SOLAR-1 phase 3 trial of alpelisib plus fulvestrant in men and postmenopausal women with advanced breast cancer that progressed on or after aromatase inhibitor treatment.
- SOLEComplete statistical analysis of the SOLE phase 3 trial of continuous versus intermittent letrozole in postmenopausal women with hormone receptor-positive, lymph node-positive, early-stage breast cancer after prior hormone therapy.
- SOPHIAIndependent statistical analysis of the SOPHIA phase 3 trial of margetuximab plus chemotherapy versus trastuzumab plus chemotherapy in HER2-positive metastatic breast cancer, including its randomized design, time-to-event endpoints, hazard ratios, confidence intervals,…
- SPARTANIndependent statistical analysis of the phase 3 SPARTAN trial of apalutamide versus placebo in men with non-metastatic castration-resistant prostate cancer, including metastasis-free survival, time to metastasis, progression-free survival, statistical methodology, safety, and…
- SPLASHIndependent statistical analysis of the phase 3 SPLASH trial evaluating [Lu-177]-PNT2002 in metastatic castration-resistant prostate cancer, including randomized design, radiographic progression-free survival, hazard-ratio methodology, and statistical interpretation.
- SPOTLIGHTComplete statistical analysis of the randomized phase 3 SPOTLIGHT trial of zolbetuximab plus chemotherapy versus placebo plus chemotherapy in adults with gastric or gastroesophageal junction adenocarcinoma, including progression-free survival, overall survival, response,…
- STARSCAPEIndependent statistical analysis of the STARSCAPE phase 3 trial of zinpentraxin alfa in idiopathic pulmonary fibrosis, including trial design, endpoints, randomized efficacy analysis, time-to-event methods, safety, limitations, and statistical interpretation.
- STELLARIndependent statistical analysis of the phase 3 STELLAR trial of sotatercept plus background PAH therapy versus placebo plus background PAH therapy in pulmonary arterial hypertension, including trial design, endpoints, nonparametric analyses, hazard…
- STROKE-AFIndependent statistical analysis of STROKE-AF (NCT02700945), a randomized trial evaluating atrial fibrillation detection through 12 months with Reveal LINQ insertable cardiac monitoring after recent ischemic stroke of presumed known origin.
- SWOG S0777Independent statistical analysis of SWOG S0777 (NCT00644228), a randomized phase 3 trial of lenalidomide and dexamethasone with or without bortezomib in previously untreated multiple myeloma.